Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
Trial details
- Registry ID
- NCT04752696
- Phase
- Phase 2
The FDA approved Fluorouracil (5-FU) on 25 Apr 1962.
Drug identity checked against registry records
Also recorded as 5-FU
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1962-04-25Day | Fluorouracil | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA012209", "applicant_as_listed_by_fda": "SPECTRUM PHARMS", "brand_names": ["FLUOROURACIL"], "active_ingredients": ["FLUOROURACIL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19620425", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |